摘要
目的分析冠状动脉粥样硬化性心脏病经皮冠状动脉介入(PCI)术后患者应用替格瑞洛对血液流变学、心肌酶谱的影响。方法样本来自2020年3月—2021年3月粤北人民医院收治的140例冠心病PCI术后患者,以随机数字表分为对照组和观察组,各70例。对照组给予氯吡格雷治疗,观察组给予替格瑞洛治疗。对血液流变学、心肌酶谱及并发症发生率进行比较分析。结果治疗后,观察组全血黏度、血浆黏度及血细胞比容水平降低较对照组明显(P<0.001),肌酸激酶同工酶(CK-MB)及肌钙蛋白I(cTnI)水平降低亦较对照组明显(P<0.001),不良反应发生率显著低于对照组(P<0.05)。结论替格瑞洛能够改善冠心病PCI术后患者的血液流变学,降低心肌酶谱指标,不良反应发生率较低,值得临床推广。
Objective To analyze the effects of tigrelol on hemorheology and myocardial enzymes in patients with coronary atherosclerotic heart disease after percutaneous coronary intervention(PCI).Methods 140 patients with coronary heart disease after PCI in Yue Bei People's Hospital from March 2020 to March 2021 were randomly divided into control group and observation group,with 70 cases in each group.The control group were treated with clopidogrel,and the observation group were treated with tigritol.And then,hemorheology,myocardial enzymes and the incidence of complications were compared and analyzed.Results After treatment,the levels of whole blood viscosity,plasma viscosity and hematocrit in the observation group were significantly lower than those in the control group(P<0.001).The levels of creatine kinase isoenzymes(CK-MB)and cardiac troponin(cTnI)in the observation group were also significantly lower than those of the control group(P<0.001),and the incidence of adverse reactions was significantly lower than that of the control group(P<0.05).Conclusion Tigrelol can improve the hemorheology of patients with coronary heart disease after PCI,reduce the index of myocardial enzyme spectrum,which has low incidence of adverse reactions,and thus is worthy of clinical promotion.
作者
杨莉军
梁万添
区永聪
YANG Lijun;LIANG Wantian;OU Yongcong(Department of Cardiovascular Diseases,Yue Bei People's Hospital,Shaoguan 512026,Guangdong,China;Department of Radiology,Yue Bei People's Hospital,Shaoguan 512026,Guangdong,China)
出处
《右江医学》
2022年第8期586-589,共4页
Chinese Youjiang Medical Journal
